Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F15%3A%230001064" target="_blank" >RIV/00064190:_____/15:#0001064 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/15:00083158 RIV/00216208:11110/15:10294524 RIV/00216208:11130/15:10294524 RIV/61989592:15110/15:33155455 and 4 more
Result on the web
<a href="http://dx.doi.org/10.1016/j.ejca.2014.12.010" target="_blank" >http://dx.doi.org/10.1016/j.ejca.2014.12.010</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejca.2014.12.010" target="_blank" >10.1016/j.ejca.2014.12.010</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency
Original language description
Aim: The aim of this retrospective, registry-based study was to analyse treatment outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib and renal insufficiency (RI). Methods: The cohort included 790 patients treated with sunitinib between 2006 and 2013. At the start of sunitinib therapy 22, 234, and 534 patients had severe (glomerular filtration rate [GFR] <30 ml/min/1.73 m(2)), moderate (GFR 30-60 ml/min/1.73 m(2)) or mild RI/normal renal function (GFR >60 ml/min/1.73 m(2)), respectively. Results: For the three groups defined above, median progression-free survival (PFS) (95% confidence interval [CI]) was 5.3 months (0.1-18.5), 8.1 months (6.2-9.9) and 11.3 months (9.4-13.2) (p = 0.244), and median overall survival (OS) was 26.3 months (1.2-51.4), 21.2 months (13.2-29.1) and 26.3 months (22.6-29.9) (p = 0.443), respectively. The disease control rates were 45.5%, 56.4% and 59.2%, respectively (p = 0.374). No unexpected toxicity was reported in the patients with RI, but the treatment was more frequently discontinued because of adverse events and the duration of therapy was significantly shorter in these patients (p = 0.007). Conclusions: Duration of first-line targeted treatment for mRCC was significantly shorter for patients with RI, and may have translated into a trend to shorter PFS. These results highlight the need for optimal management of side-effects in patients with mRCC and RI.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EUROPEAN JOURNAL OF CANCER
ISSN
0959-8049
e-ISSN
—
Volume of the periodical
51
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
507-513
UT code for WoS article
000350915600008
EID of the result in the Scopus database
—